The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria

被引:0
作者
Christos Sachpekidis
Vivienn Weru
Annette Kopp-Schneider
Jessica C. Hassel
Antonia Dimitrakopoulou-Strauss
机构
[1] Clinical Cooperation Unit Nuclear Medicine,Department of Dermatology and National Center for Tumor Diseases (NCT)
[2] German Cancer Research Center (DKFZ),undefined
[3] Department of Biostatistics,undefined
[4] German Cancer Research Center (DKFZ),undefined
[5] University Hospital Heidelberg,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词
Metastatic melanoma; Immune checkpoint inhibitors (ICIs); Immunotherapy; Treatment response evaluation; [; F]FDG PET/CT; Metabolic response criteria;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2699 / 2714
页数:15
相关论文
共 173 条
[1]  
Robert C(2020)A decade of immune-checkpoint inhibitors in cancer therapy Nat Commun 11 3801-1014
[2]  
Khair DO(2019)Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma Front Immunol 10 453-670
[3]  
Bax HJ(2021)Immune checkpoint inhibitors in melanoma Lancet 398 1002-1189
[4]  
Mele S(2022)A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance Nat Immunol 23 660-538
[5]  
Carlino MS(2019)5-year results for pembrolizumab treatment of advanced melanoma Lancet Oncol 20 1187-396
[6]  
Larkin J(2015)Cancer and the Immune System: Basic Concepts and Targets for Intervention Semin Oncol 42 523-264
[7]  
Long GV(2019)Novel patterns of response under immunotherapy Ann Oncol 30 385-448
[8]  
Huang AC(2022)18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer Radiology 304 246-1428
[9]  
Zappasodi R(2019)Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors J Immunother Cancer 7 306-383
[10]  
Hassel JC(2020)Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis BMC Med 18 87-341